U.S. Markets closed
  • S&P 500

    +100.40 (+2.47%)
  • Dow 30

    +575.77 (+1.76%)
  • Nasdaq

    +390.48 (+3.33%)
  • Russell 2000

    +49.66 (+2.70%)
  • Crude Oil

    +0.98 (+0.86%)
  • Gold

    +3.40 (+0.18%)
  • Silver

    +0.17 (+0.77%)

    +0.0006 (+0.0537%)
  • 10-Yr Bond

    -0.0130 (-0.47%)
  • Vix

    -1.78 (-6.47%)

    +0.0025 (+0.2021%)

    -0.0170 (-0.0134%)

    +130.12 (+0.45%)
  • CMC Crypto 200

    -3.71 (-0.59%)
  • FTSE 100

    +20.54 (+0.27%)
  • Nikkei 225

    +176.84 (+0.66%)

StemoniX Announces Publication Demonstrating High-throughput Screening Using Human-derived CNS Models

·3 min read

MAPLE GROVE, MN and SAN DIEGO, CA / ACCESSWIRE / November 12, 2020 / StemoniX, Inc. announced the publication of a new research paper, "Screening for modulators of neural network activity in 3D human iPSC-derived cortical spheroids," in the journal PLOS ONE. The research describes how the StemoniX microBrain 3D platform can be used in functional high-throughput screens to identify potentially new therapeutics for central nervous system (CNS) indications.

microBrain® 3D is an advanced, biologically-relevant human neural spheroid platform comprised of neurons and astrocytes, with complex biological structure that is ideal for interrogating a wide range of human CNS biology. The publication describes how scientists screened a library of over 1200 diverse compounds to highlight cellular pathways present in microBrain 3D. The authors indicate that the wide-range of relevant neurobiology as well as the consistency and reproducibility of the responses demonstrates the suitability of the system for CNS-based drug discovery.

"CNS diseases have proven to be especially difficult to treat, in part due to a lack of models that accurately reflect the human brain. Fortunately, the technological innovations and higher throughput of our advanced human-based neural platform overcomes this hurdle and allows researchers to better predict efficacy and potential toxicities of developing therapeutics," noted Ping Yeh, StemoniX CEO and Co-founder. "By putting human biology first in the drug discovery pipeline, we're de-risking the process and ensuring that the best molecules are developed. We believe this approach is the future of discovery and development."

In August, StemoniX and Cancer Genetics, Inc. (Nasdaq: CGIX) announced a definitive agreement to merge. Combined, the two companies will span the drug development life cycle from early stage discovery through late pre-clinical trials. The merger is expected to be completed early in Q1 2021.

ABOUT STEMONIX, INC. StemoniX is empowering the discovery of new medicines through the convergence of novel human biology and software technologies. StemoniX develops and manufactures high-density, at-scale human induced pluripotent stem (iPSC) cell-derived neural and cardiac screening platforms for drug discovery and development. Predictive, accurate, and consistent, these human models enable scientists to quickly and economically conduct research with improved outcomes in a simplified workflow. Through collaborations with drug discovery organizations, StemoniX tests compounds in-house, creates new cell-based disease models, and operationalizes custom human iPSC disease models at large scale for high-throughput screening. With leading-edge iPSC technologies and data science, StemoniX is helping global institutions bring the most promising medicines to patients. To learn more about how StemoniX products and services are accelerating discoveries, please visit www.StemoniX.com.

Forward Looking Statement: This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). StemoniX Inc.'s disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, statements relating to StemoniX Inc.'s research activities, expectations of current and future board member activities, future financial and/or operating results, and potential for our services, future revenues or growth. Any statements that are not historical fact (including, but not limited to, statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties. Such statements are based on current expectations, but actual results may differ due to a variety of risks and uncertainties.

Investor Contact:
Ping Yeh, CEO
StemoniX, Inc.
Email: ping.yeh@stemonix.com
Phone: (612) 807-9889

SOURCE: StemoniX, Inc.


View source version on accesswire.com: